A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug combination called Imprime PGG and Rituximab as a
possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).